Start-Up Stadium

Presenting Finalists for Start-Up Stadium benefit from exposure to investors, discounted registration fees, and access to BIO One-on-One Partnering™.  

What Kind of Exposure do Applicants Receive?

The goal of Start-up Stadium is to increase start-ups’ engagement and visibility with investors, state and regional affiliates, and early-stage companies at the beginning of their life-cycle. All applications were reviewed by judges experienced in evaluation of start-ups' growth potential as companies.  During the BIO International Convention, investor judges will attend live start-up presentations and engage in  Q&A/feedback with start-up finalists.

Don't miss out on this exciting opportunity to meet the finalists and hear their pitches during sessions on June 14, 15, and 16.

Who can participate? Companies that have...

• Raised less than $10M since inception
• Previous business pitch or competition experience
• Fewer than 20 full-time employees
• Not previously been named a BIO Start-Up Stadium winner

Have additional questions? Download the Start-Up Stadium Pitch Guide Instructions here.

BIO Thanks the 2022 Start-Up Stadium Judges:

• Orrin Ailloni-Charas, MD, MBA, Managing Partner, Cura Capital

• Christopher Aleong, Chief Business Officer, Lumosa Therapeutics

• John Behr, Partner, SV Health Investors

• James Buxton, Senior Associate, NEA

• Joseph Charalel, Senior Associate, Pivotal bioVenture Partners (US)

• David H. Crean, Managing General Partner, Cardiff Advisory LLC

• Bettina Ernst, Director, BERNINA BioInvest

• David Fox, Co-founder, Modality.ai

• Yinghong Gao, Venture Partner, Viva BioInnovator

• Juliet Gomez, Program Manager, Flinn Foundation

• Gábor Gyülvészi, Sr. Associate, Nextech Invest AG

• Lu Han, Partner, Lumira Ventures

• Daniel Jacobs, Managing Director, Pathway Bioventures

• Scott M. Kahn, PhD, Founder, Alykomed Global Solutions LLC

• Vince Kohli, Global Tech Impact Capitalist, Trillion Ventures Global Capital Fund

• Benjamin Li, Senior Associate, Pivotal bioVenture Partners (US)

• David Malek, Venture Partner, Pivotal bioVenture Partners (US)

• Marc Martin-Casas, Head of Illumina Accelerator, San Francisco, Illumina Accelerator

• Laurie K. McNamara, PhD, Esq., Associate, Wilson Sonsini Goodrich & Rosati

• Miguel A. Mendez, Managing Director, Facultas Partners

• Mariana Mihalusova, Vice President, Venrock

• Sandra Miller, General Partner, Cura Capital

• Graham Mills, Investment Manager, Abingworth LLP

• Ivan Morace, Senior Investment Analyst, MediVentures GmbH

• Anton Neschadim, Senior Advisor, GreenSky Capital

• Younes Ouahid, Partner, Facultas Partners

• William D. Provine, PhD, President & CEO, Innovation Space

• Marcie Reilly, Program Manager, Partnerships & Special Projects, Innovation Space

• Catello Somma, Associate, TVM Capital Life Science Management GmbH

• Lesley Stolz, PhD, VP, Early Innovation Partnering, Johnson & Johnson Innovation

• Nilay Thakar, Principal, ARCH Venture Partners

• Anton Xavier, Director, Early Stage Life Science Banking, SVB

• Kitty Wu, VP, Head of Business Development and Strategy, Fosun Pharma USA

• Samuel Wu, Venture Partner, 7G BioVentures

• Xiangbin Xu, CEO, QLD Biotherapeutics Inc

• Wenping Zhou, Investment Associate, CT innovations

• John Zhu, Founder and President, Mayewell Capital